GLP-1 Medications for MASH and Fatty Liver: The Evidence Map

Key Takeaways

• Semaglutide ESSENCE phase 3 met both FDA-defined MASH endpoints in 2025; an FDA filing for a MASH indication is anticipated but not yet granted
• Tirzepatide SYNERGY-NASH phase 2 showed positive direction-of-effect results in 2024; phase 3 ongoing
• Rezdiffra (resmetirom) is the first FDA-approved MASH drug (March 2024); it is not a GLP-1 and has a complementary mechanism
• Weight loss appears to drive a substantial fraction of GLP-1 benefit in MASH, but direct anti-inflammatory and insulin-sensitizing mechanisms also contribute
• For clinical use today, MASH patients access GLP-1 medications through diabetes or obesity indications until a formal MASH approval lands

Direct answer

GLP-1 medications show solid evidence of benefit in metabolic dysfunction-associated steatohepatitis (MASH), with the semaglutide ESSENCE phase 3 trial meeting both FDA co-primary endpoints in 2025 and tirzepatide SYNERGY-NASH phase 2 showing positive results in 2024. No GLP-1 medication holds FDA approval for MASH as of May 2026; Rezdiffra (resmetirom) is currently the only FDA-approved MASH drug, with a different mechanism. The regulatory pathway for semaglutide in MASH is active, and a future approval is plausible. Until then, MASH patients access GLP-1 medications through paired diabetes or obesity diagnoses.

Table of contents

1. MASLD, MASH, and why both names matter
2. The semaglutide story: from phase 2 to ESSENCE
3. Tirzepatide and SYNERGY-NASH
4. Rezdiffra (resmetirom): the comparison most patients want
5. How each drug actually works on liver tissue
6. Endpoints, biopsies, and the FDA approval bar
7. Where simple steatosis sits in the treatment ladder
8. Other agents in the pipeline (survodutide, efimosfermin, others)
9. The combination question
10. The contrary view: where the evidence is still weak
11. Decision framework
12. FAQ
13. Sources

MASLD, MASH, and why both names matter

The 2023 nomenclature update replaced NAFLD with MASLD (metabolic dysfunction-associated steatotic liver disease) and NASH with MASH (metabolic dysfunction-associated steatohepatitis). The change reflects a definitional shift toward positive metabolic criteria rather than the older negative framing ("non-alcoholic").

For practical purposes, MASLD and NAFLD describe the same spectrum, as do MASH and NASH. Trial literature, FDA labels, and society guidelines published since mid-2023 use the new terminology. Older sources continue to use the legacy terms. Patients sometimes see both used interchangeably in clinical conversations.

The MASLD spectrum:

• MASL (simple steatosis). Hepatic fat without significant inflammation or hepatocyte injury. Generally benign in isolation.
• MASH. Steatosis with inflammation and ballooning hepatocyte injury. Progressive risk.
• Fibrosis (F0-F4). Scarring response to chronic injury, staged from none (F0) to cirrhosis (F4).

FDA approvals for liver-specific MASH drugs target the F2-F3 fibrosis tier, where progression risk is meaningful but reversal is still feasible. Simple steatosis rarely justifies pharmacotherapy.

The semaglutide story: from phase 2 to ESSENCE

Semaglutide's MASH program started with phase 2 data in 2021 (Newsome et al., NEJM 2021). Highlights from that trial:

• 320 patients with biopsy-confirmed NASH and F1-F3 fibrosis
• Semaglutide 0.1, 0.2, or 0.4 mg daily versus placebo (note: daily, not weekly)
• 72-week treatment
• NASH resolution without fibrosis worsening: 59% on highest dose vs 17% placebo (statistically significant)
• Fibrosis improvement: did not reach statistical significance in primary analysis

The phase 2 result was promising for the MASH resolution endpoint but mixed for fibrosis. Novo Nordisk moved to phase 3 with the higher-dose, less-frequent regimen (semaglutide 2.4 mg weekly, the Wegovy obesity dose).

ESSENCE design summary:

• Approximately 1,200 adults with biopsy-confirmed MASH and F2 or F3 fibrosis
• Semaglutide 2.4 mg weekly versus placebo, 2:1 randomization
• Primary analysis at 72 weeks (paired biopsy); long-term outcome extension to 240 weeks
• Co-primary endpoints: MASH resolution without fibrosis worsening, and fibrosis improvement (≥1 stage) without MASH worsening

Top-line 2025 results (approximate, from published top-line release):

• MASH resolution without fibrosis worsening: ~62% semaglutide vs ~34% placebo (p < 0.001)
• Fibrosis improvement without MASH worsening: ~37% semaglutide vs ~22% placebo (p < 0.001)
• Body weight reduction: ~10% semaglutide vs ~0.8% placebo
• HbA1c improvements in the diabetic subgroup
• Adverse event profile consistent with known semaglutide profile

The data support a regulatory filing for a MASH indication. The timeline for FDA action depends on submission and review pace.

Tirzepatide and SYNERGY-NASH

Eli Lilly ran a phase 2 trial of tirzepatide in MASH with F2-F3 fibrosis. Loomba et al. (2024) reported:

• Approximately 190 patients
• Tirzepatide 5, 10, or 15 mg weekly versus placebo
• 52-week treatment, paired biopsy
• MASH resolution without fibrosis worsening: 44%, 56%, and 62% across doses, vs ~10% placebo
• Fibrosis improvement: 55%, 51%, and 51% across doses, vs ~30% placebo (not all dose comparisons statistically significant)
• Substantial weight loss across all doses

Phase 3 (SURMOUNT-MASH or similar branded program) is in design or early enrollment as of May 2026. Approval timing is later than semaglutide.

The pattern across both programs: dual incretin (tirzepatide) and single GLP-1 (semaglutide) both produce meaningful MASH resolution. Fibrosis improvement is more variable across studies and dose levels, but the direction of effect is consistent.

Rezdiffra (resmetirom): the comparison most patients want

Resmetirom (Rezdiffra) became the first FDA-approved drug for MASH in March 2024, based on the MAESTRO-NASH trial (Harrison et al., NEJM 2024). Highlights:

• 966 adults with biopsy-confirmed MASH and F1B-F3 fibrosis
• Resmetirom 80 mg or 100 mg daily versus placebo
• 52-week paired biopsy
• MASH resolution without fibrosis worsening: 26% (80 mg), 30% (100 mg), 10% placebo
• Fibrosis improvement by ≥1 stage without MASH worsening: 24% (80 mg), 26% (100 mg), 14% placebo
• Modest weight loss (~3-5%) and lipid improvements

The MAESTRO numbers are smaller than the semaglutide ESSENCE numbers for MASH resolution, but Rezdiffra's mechanism is more liver-targeted. Comparing across trials is risky (different populations, durations, dosing), so the direct comparison is impressionistic.

Feature	Rezdiffra (resmetirom)	Semaglutide (ESSENCE)	Tirzepatide (SYNERGY-NASH phase 2)
FDA status (May 2026)	Approved for MASH F2-F3	Filing anticipated	Phase 3 ongoing
Mechanism	THR-β agonism, direct liver action	GLP-1 receptor agonism, weight + metabolic	Dual GIP/GLP-1 receptor agonism
Trial duration to primary endpoint	52 weeks	72 weeks	52 weeks
MASH resolution rate (drug vs placebo)	~26-30% vs 10%	~62% vs 34%	~44-62% vs 10%
Fibrosis improvement rate (drug vs placebo)	~24-26% vs 14%	~37% vs 22%	~51-55% vs 30%
Weight loss	~3-5%	~10%	~13-18% across doses
Annual list price	~$47,000	~$11,000-16,000 (when MASH-approved)	TBD
Administration	Oral daily	Subcutaneous weekly	Subcutaneous weekly

The way to read this: Rezdiffra is more liver-focused with smaller systemic effects. The GLP-1 medications are broader metabolic interventions whose liver benefit comes alongside weight, glycemic, and cardiovascular effects. For patients whose MASH coexists with obesity or diabetes, GLP-1 covers more ground. For patients without major comorbidities but with established MASH and fibrosis, Rezdiffra is the targeted option.

How each drug actually works on liver tissue

Mechanistic understanding helps explain the trial results.

GLP-1 receptor agonism in MASH:

• Weight loss reduces hepatic fat by reducing free fatty acid flux from adipose tissue
• Improved insulin sensitivity reduces de novo lipogenesis in hepatocytes
• Reduced systemic inflammation lowers cytokine burden on liver
• Possible direct effects on hepatic stellate cells and macrophages (mechanism unsettled)
• Reduced postprandial glucose and lipid swings reduce liver substrate load

THR-β agonism in MASH (Rezdiffra):

• Activates liver-specific thyroid hormone receptor beta
• Increases hepatic fatty acid oxidation
• Reduces hepatic triglyceride synthesis
• Improves LDL clearance
• Direct anti-fibrotic effect via stellate cell modulation
• Limited systemic thyroid effects (selectivity for beta vs alpha receptor)

The non-overlap is the rationale for theoretical combination therapy. GLP-1 reduces the substrate; Rezdiffra increases the disposal. Whether combination produces additive benefit clinically has not been formally studied.

Endpoints, biopsies, and the FDA approval bar

FDA endpoints for MASH drug approval are:

1. MASH resolution without worsening of fibrosis, OR
2. Improvement in fibrosis by at least one stage without worsening of MASH

The FDA has used these endpoints because long-term outcomes (cirrhosis, liver-related mortality) take decades to assess. The agency accepts the histological surrogates with the requirement that long-term outcome trials continue post-approval.

Biopsy is the gold-standard endpoint because the histology defines the disease. The downsides are real: biopsy is invasive, samples a tiny fraction of the liver, and has inter-reader variability for staging. Non-invasive tests are increasingly used in clinical care but are not yet primary regulatory endpoints.

Common non-invasive tests:

• FibroScan (transient elastography) with controlled attenuation parameter
• MRE (magnetic resonance elastography)
• ELF (enhanced liver fibrosis) blood test
• FIB-4 score (calculated from age, AST, ALT, platelets)
• NAFLD fibrosis score

For clinical practice, most patients are staged with one of these rather than biopsy. For trial enrollment in MASH-targeted drug programs, biopsy is still standard.

Where simple steatosis sits in the treatment ladder

Simple steatosis (MASL) is fatty liver without significant inflammation or fibrosis. It is highly prevalent (estimates range 25-35% of U.S. adults have some degree of hepatic steatosis). Most cases do not progress to MASH or cirrhosis.

Treatment for MASL is mostly lifestyle:

• Weight loss of 5-10% reverses most simple steatosis
• Mediterranean dietary pattern
• Reduction of fructose-sweetened beverages
• Aerobic exercise (3+ hours weekly) improves liver fat independent of weight
• Resistance training adds benefit
• Alcohol reduction (especially relevant if "lean MASLD" co-exists with metabolic dysfunction)

Pharmacotherapy for simple steatosis is rarely indicated. If a patient with MASL also has obesity, diabetes, or cardiovascular risk, the medications used for those indications (GLP-1, SGLT2 inhibitors) will incidentally improve hepatic fat. The MASL itself is not usually the prescribing reason.

Other agents in the pipeline (survodutide, efimosfermin, others)

The MASH drug pipeline is crowded. Key non-GLP-1 (or partial GLP-1) candidates:

Agent	Mechanism	Status (May 2026)
Survodutide (Boehringer/Zealand)	Glucagon/GLP-1 dual agonist	Phase 3 program in MASH
Efimosfermin (FGF21 analog)	Hepatic-targeted metabolic modulator	Phase 2/3
Pegozafermin (FGF21 analog)	Hepatic-targeted	Phase 3
Lanifibranor	Pan-PPAR agonist	Phase 3
Aldafermin	FGF19 analog	Phase 2/3 mixed results
Semaglutide (Novo Nordisk)	GLP-1	ESSENCE phase 3 positive, filing anticipated
Tirzepatide (Eli Lilly)	GIP/GLP-1	Phase 3

The likely 2027-2029 picture: multiple approved MASH drugs across different mechanisms, with combination therapy emerging as the standard for advanced fibrosis. Survodutide gets its own deeper-dive article (AEO-3583) given its specific dual mechanism.

The combination question

Combination therapy (Rezdiffra + GLP-1, or future combinations like Rezdiffra + FGF21 analog) has theoretical appeal because the mechanisms are non-overlapping. The clinical case is unproven.

Practical issues:

• No randomized trial data on combination safety or additive efficacy
• Insurance plans rarely cover two MASH-targeted drugs simultaneously
• Costs stack (Rezdiffra ~$47,000/year plus GLP-1 ~$11,000-16,000/year)
• Side effect burden adds up

Tertiary academic hepatology centers sometimes use combination in advanced fibrosis. General practice rarely does. The evidence base will mature over the next several years.

The contrary view: where the evidence is still weak

Gap 1: Long-term outcome data. MASH trials use histological surrogates. Whether the histological improvements translate to reduced cirrhosis, hepatocellular carcinoma, and liver-related mortality requires decades-long follow-up. Post-approval outcome studies are ongoing.

Gap 2: Discontinuation effects. If a patient stops a GLP-1 medication after MASH resolution, does the fatty liver return? Probably yes, in proportion to weight regain, but discontinuation data in MASH are sparse.

Gap 3: Mechanism attribution. Weight loss accounts for a substantial fraction of GLP-1 MASH benefit, but the exact contribution of weight versus direct anti-inflammatory and insulin-sensitizing effects is not cleanly separable.

Gap 4: Patients without obesity or diabetes. ESSENCE enrolled MASH patients across the metabolic spectrum, but the mean BMI was elevated. Lean MASH (estimated 10-20% of MASH cases) is studied less.

Gap 5: Pediatric MASH. Pediatric MASH is a growing public health concern. GLP-1 trials in pediatric MASH have not yet reported.

Decision framework

If you have MASH with F2-F3 fibrosis and obesity or diabetes: A GLP-1 medication targets multiple problems simultaneously. Insurance coverage is typically available through the diabetes or obesity indication.

If you have MASH with F2-F3 fibrosis without major comorbidity: Rezdiffra is the FDA-approved targeted option. Coverage exists with strict prior authorization. A future semaglutide MASH approval would expand options.

If you have simple steatosis (MASL): Lifestyle change first. Pharmacotherapy is rarely needed. If you have obesity or diabetes, the GLP-1 indication is the comorbidity, not the steatosis.

If you have advanced fibrosis approaching cirrhosis: Hepatologist co-management is essential. Some pharmacotherapy options become inappropriate at advanced stages.

If you have decompensated cirrhosis: Most MASH drug trials exclude this population. Care focuses on managing complications and transplant evaluation, not on disease reversal.

FAQ

Do GLP-1 medications work for MASH?

Yes, in the trial sense. Semaglutide ESSENCE met both FDA-defined MASH endpoints in 2025. Tirzepatide SYNERGY-NASH phase 2 showed positive direction-of-effect results in 2024. No GLP-1 is FDA-approved for MASH yet; filings are anticipated.

How does semaglutide compare to Rezdiffra?

Different mechanisms. Rezdiffra is liver-targeted thyroid hormone receptor beta agonism; semaglutide is GLP-1 with broader systemic effects. Both meet MASH endpoints in their trials. No head-to-head data exist.

What about tirzepatide for MASH?

Phase 2 SYNERGY-NASH positive in 2024. Phase 3 in progress. Approval is plausible but later than semaglutide.

Will GLP-1 cure my fatty liver?

Treatment, not cure. Steatosis can reverse, MASH can resolve, fibrosis can improve. Whether benefit persists after stopping the medication is uncertain; most clinicians frame this as long-term management.

Is weight loss the only mechanism?

Not entirely. Weight loss is a major mediator. Insulin sensitization, anti-inflammatory effects, and possible direct hepatocyte effects also contribute.

What if I have simple steatosis?

Pharmacotherapy is rarely indicated. Lifestyle change reverses most cases.

Do I need a liver biopsy?

For clinical trial enrollment, yes. For clinical practice, non-invasive testing is increasingly accepted.

Can I combine GLP-1 with Rezdiffra?

Theoretically attractive, not formally studied. Combination is uncommon outside academic hepatology.

What is the difference between MASLD and NAFLD?

Same disease, updated 2023 nomenclature. MASLD is the current term; NAFLD is the legacy term.

What stages benefit most?

Trial enrollment was typically F2-F3 fibrosis with MASH. Earlier stages may benefit too, but trials did not enroll them. F4 (cirrhosis) was generally excluded.

How long do I take it?

Open question. The trials report results at 52-72 weeks. Long-term outcome data are accruing. Most clinicians frame this as long-term therapy.

What are the side effects?

For GLP-1: nausea, GI upset, possible gallbladder events, rare pancreatitis. For Rezdiffra: diarrhea, transient liver enzyme elevations. Side effect profiles are well-characterized in trial data.

Related guides

• Fatty Liver Disease and Peptides: NAFLD Treatment Options
• Semaglutide for Fatty Liver: What the Research Shows
• Can Peptides Help With Fatty Liver Disease
• Has Anyone Gotten Cancer from Ozempic? The Clinical Evidence on GLP-1 Medications and Cancer Risk
• GLP-1 Medications for PCOS: What the Evidence Actually Shows
• GLP-1 Medications for Sleep Apnea: The SURMOUNT-OSA Evidence

Sources

1. Rinella ME et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Annals of Hepatology. 2023.
2. ESSENCE Trial. Top-line release for semaglutide 2.4 mg in MASH F2-F3. 2025.
3. Newsome PN et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. NEJM. 2021.
4. Loomba R et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis With Liver Fibrosis (SYNERGY-NASH). 2024.
5. Harrison SA et al. Resmetirom (MGL-3196) for the treatment of nonalcoholic steatohepatitis (MAESTRO-NASH). NEJM. 2024.
6. FDA Drug Label. Rezdiffra (resmetirom). 2024.
7. AASLD Practice Guidance: Management of MASLD. 2023 update.
8. EASL-EASD-EASO Clinical Practice Guidelines on the management of MASLD. 2024.
9. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM. 2021.
10. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM. 2022.
11. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). NEJM. 2023.
12. FDA Guidance for Industry: Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment. 2018 (updated guidance pending).
13. Sanyal AJ et al. Pegozafermin in NASH (ENLIVEN). NEJM. 2023.
14. Younossi ZM et al. Global epidemiology of nonalcoholic fatty liver disease. Hepatology. 2023 update.

Footer disclaimers

Platform Disclaimer. FormBlends provides educational information and connects patients with independent licensed providers. We do not prescribe directly. Liver disease evaluation and treatment require specialist involvement (hepatology or gastroenterology). This article is not a substitute for personalized clinical advice.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved and have not been studied for MASH specifically. Compounded medications are prepared by state-licensed 503A pharmacies pursuant to individual prescriptions. They are not interchangeable with brand-name products.

Results Disclaimer. Trial results describe averages across populations and primary endpoints. Individual response in MASH varies by fibrosis stage, comorbidities, adherence, and other factors. Statements about future FDA approvals reflect best information available as of May 2026.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Rezdiffra is a registered trademark of Madrigal Pharmaceuticals. FormBlends is not affiliated with, endorsed by, or sponsored by these companies.